APO Research
Talk to an analyst

APO RESEARCH · REPORT

Novel Oral AntiCoagulants (NOAC)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Novel Oral AntiCoagulants (NOAC) Market Outlook and Growth Opportunities 2026

26 December 2025201 pages

Choose your research edition.

Industry ResearchNovel Oral AntiCoagulants (NOAC) Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Novel Oral AntiCoagulants (NOAC) Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Novel Oral AntiCoagulants (NOAC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Novel Oral AntiCoagulants (NOAC) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Novel Oral AntiCoagulants (NOAC) Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Novel Oral AntiCoagulants (NOAC) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Novel Oral AntiCoagulants (NOAC) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Novel Oral AntiCoagulants (NOAC) market include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Novel Oral AntiCoagulants (NOAC) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Novel Oral AntiCoagulants (NOAC) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Novel Oral AntiCoagulants (NOAC) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Novel Oral AntiCoagulants (NOAC) market size, projected growth trends, production technologies, key applications, and end-use industries.

Novel Oral AntiCoagulants (NOAC) Segment by Company

Armatheon

Aspen

Boehringer Ingelheim

Bristol-Myers Squibb

Cellceutix

Cosmo Pharmaceuticals

CSL Behring

Daiichi Sankyo

Marathon Pharmaceuticals

Ockham Biotech

Perosphere

AstraZeneca

Bayer

GSK

Johnson & Johnson

Sanofi

Eisai

Novel Oral AntiCoagulants (NOAC) Segment by Type

Direct Thrombin Inhibitors

Direct Factor Xa Inhibitors

Novel Oral AntiCoagulants (NOAC) Segment by Application

Hemodialysis

Deep Vein Thrombosis (DVT)

Acute Coronary Syndrome

Pulmonary Embolism

Others

Novel Oral AntiCoagulants (NOAC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Novel Oral AntiCoagulants (NOAC) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Novel Oral AntiCoagulants (NOAC) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Novel Oral AntiCoagulants (NOAC) significant trends, drivers, influence factors in global and regions.

6. To analyze Novel Oral AntiCoagulants (NOAC) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Novel Oral AntiCoagulants (NOAC) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Novel Oral AntiCoagulants (NOAC) industry.

Chapter 3: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Novel Oral AntiCoagulants (NOAC) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Novel Oral AntiCoagulants (NOAC) Industry Trends Table 2. Novel Oral AntiCoagulants (NOAC) Industry Drivers Table 3. Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges Table 4. Novel Oral AntiCoagulants (NOAC) Industry Restraints Table 5. Global Novel Oral AntiCoagulants (NOAC) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Novel Oral AntiCoagulants (NOAC) Revenue Share by Company (2021-2026) Table 7. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Company (2021-2026) Table 9. Global Novel Oral AntiCoagulants (NOAC) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Novel Oral AntiCoagulants (NOAC) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Novel Oral AntiCoagulants (NOAC) Key Company Manufacturing Base & Headquarters Table 12. Global Novel Oral AntiCoagulants (NOAC) Company, Product Type & Application Table 13. Global Novel Oral AntiCoagulants (NOAC) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Novel Oral AntiCoagulants (NOAC) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Direct Thrombin Inhibitors Table 18. Significant Companies of Direct Factor Xa Inhibitors Table 19. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Type (2021-2026) Table 23. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Type (2027-2032) Table 24. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type (2021-2026) Table 28. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hemodialysis Table 30. Significant Companies of Deep Vein Thrombosis (DVT) Table 31. Significant Companies of Acute Coronary Syndrome Table 32. Significant Companies of Pulmonary Embolism Table 33. Significant Companies of Others Table 34. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Application (2021-2026) Table 38. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Application (2027-2032) Table 39. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application (2021-2026) Table 43. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application (2027-2032) Table 44. Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026) & (W Units) Table 46. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2021-2026) Table 47. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2027-2032) & (W Units) Table 48. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2027-2032) Table 49. Global Novel Oral AntiCoagulants (NOAC) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Region (2021-2026) Table 52. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Region (2027-2032) Table 54. Global Novel Oral AntiCoagulants (NOAC) Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Novel Oral AntiCoagulants (NOAC) Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 59. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2026) Table 60. Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 61. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2027-2032) Table 62. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Novel Oral AntiCoagulants (NOAC) Sales Value Market Share by Country (2021-2026) Table 64. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Novel Oral AntiCoagulants (NOAC) Sales Value Market Share by Country (2027-2032) Table 66. Armatheon Company Information Table 67. Armatheon Business Overview Table 68. Armatheon Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 70. Armatheon Recent Development Table 71. Aspen Company Information Table 72. Aspen Business Overview Table 73. Aspen Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 75. Aspen Recent Development Table 76. Boehringer Ingelheim Company Information Table 77. Boehringer Ingelheim Business Overview Table 78. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 80. Boehringer Ingelheim Recent Development Table 81. Bristol-Myers Squibb Company Information Table 82. Bristol-Myers Squibb Business Overview Table 83. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 85. Bristol-Myers Squibb Recent Development Table 86. Cellceutix Company Information Table 87. Cellceutix Business Overview Table 88. Cellceutix Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 90. Cellceutix Recent Development Table 91. Cosmo Pharmaceuticals Company Information Table 92. Cosmo Pharmaceuticals Business Overview Table 93. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 95. Cosmo Pharmaceuticals Recent Development Table 96. CSL Behring Company Information Table 97. CSL Behring Business Overview Table 98. CSL Behring Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 100. CSL Behring Recent Development Table 101. Daiichi Sankyo Company Information Table 102. Daiichi Sankyo Business Overview Table 103. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 105. Daiichi Sankyo Recent Development Table 106. Marathon Pharmaceuticals Company Information Table 107. Marathon Pharmaceuticals Business Overview Table 108. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 110. Marathon Pharmaceuticals Recent Development Table 111. Ockham Biotech Company Information Table 112. Ockham Biotech Business Overview Table 113. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 115. Ockham Biotech Recent Development Table 116. Perosphere Company Information Table 117. Perosphere Business Overview Table 118. Perosphere Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 120. Perosphere Recent Development Table 121. AstraZeneca Company Information Table 122. AstraZeneca Business Overview Table 123. AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 125. AstraZeneca Recent Development Table 126. Bayer Company Information Table 127. Bayer Business Overview Table 128. Bayer Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 130. Bayer Recent Development Table 131. GSK Company Information Table 132. GSK Business Overview Table 133. GSK Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 135. GSK Recent Development Table 136. Johnson & Johnson Company Information Table 137. Johnson & Johnson Business Overview Table 138. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 140. Johnson & Johnson Recent Development Table 141. Sanofi Company Information Table 142. Sanofi Business Overview Table 143. Sanofi Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 145. Sanofi Recent Development Table 146. Eisai Company Information Table 147. Eisai Business Overview Table 148. Eisai Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 150. Eisai Recent Development Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. Novel Oral AntiCoagulants (NOAC) Distributors List Table 154. Novel Oral AntiCoagulants (NOAC) Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Novel Oral AntiCoagulants (NOAC) Product Image Figure 2. Global Novel Oral AntiCoagulants (NOAC) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Novel Oral AntiCoagulants (NOAC) Sales (2021-2032) & (W Units) Figure 5. Global Novel Oral AntiCoagulants (NOAC) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Novel Oral AntiCoagulants (NOAC) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Direct Thrombin Inhibitors Image Figure 10. Direct Factor Xa Inhibitors Image Figure 11. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Type (2021-2032) Figure 14. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type (2021-2032) Figure 17. Hemodialysis Image Figure 18. Deep Vein Thrombosis (DVT) Image Figure 19. Acute Coronary Syndrome Image Figure 20. Pulmonary Embolism Image Figure 21. Others Image Figure 22. Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Application (2021-2032) Figure 25. Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application (2021-2032) Figure 28. Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Novel Oral AntiCoagulants (NOAC) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032) & (US$ Million) Figure 33. North America Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032) & (US$ Million) Figure 39. South America Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Novel Oral AntiCoagulants (NOAC) Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Novel Oral AntiCoagulants (NOAC) Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Direct Thrombin Inhibitors
  • Direct Factor Xa Inhibitors
Applications
  • Hemodialysis
  • Deep Vein Thrombosis (DVT)
  • Acute Coronary Syndrome
  • Pulmonary Embolism
  • Others
Companies covered
  • Armatheon
  • Aspen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cellceutix
  • Cosmo Pharmaceuticals
  • CSL Behring
  • Daiichi Sankyo
  • Marathon Pharmaceuticals
  • Ockham Biotech
  • Perosphere
  • AstraZeneca
  • Bayer
  • GSK
  • Johnson & Johnson
  • Sanofi
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032)
  4. 1.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume (2021-2032)
  5. 1.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Novel Oral AntiCoagulants (NOAC) Market Dynamics
  1. 2.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
  2. 2.2 Novel Oral AntiCoagulants (NOAC) Industry Drivers
  3. 2.3 Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges
  4. 2.4 Novel Oral AntiCoagulants (NOAC) Industry Restraints
3 Novel Oral AntiCoagulants (NOAC) Market by Company
  1. 3.1 Global Novel Oral AntiCoagulants (NOAC) Company Revenue Ranking in 2025
  2. 3.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Company (2021-2026)
  3. 3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Company (2021-2026)
  4. 3.4 Global Novel Oral AntiCoagulants (NOAC) Average Price by Company (2021-2026)
  5. 3.5 Global Novel Oral AntiCoagulants (NOAC) Company Ranking (2024-2026)
  6. 3.6 Global Novel Oral AntiCoagulants (NOAC) Company Manufacturing Base and Headquarters
  7. 3.7 Global Novel Oral AntiCoagulants (NOAC) Company Product Type and Application
  8. 3.8 Global Novel Oral AntiCoagulants (NOAC) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Novel Oral AntiCoagulants (NOAC) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Novel Oral AntiCoagulants (NOAC) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Novel Oral AntiCoagulants (NOAC) Market by Type
  1. 4.1 Novel Oral AntiCoagulants (NOAC) Type Introduction
  2. 4.1.1 Direct Thrombin Inhibitors
  3. 4.1.2 Direct Factor Xa Inhibitors
  4. 4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type
  5. 4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type
  9. 4.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type (2021-2032)
5 Novel Oral AntiCoagulants (NOAC) Market by Application
  1. 5.1 Novel Oral AntiCoagulants (NOAC) Application Introduction
  2. 5.1.1 Hemodialysis
  3. 5.1.2 Deep Vein Thrombosis (DVT)
  4. 5.1.3 Acute Coronary Syndrome
  5. 5.1.4 Pulmonary Embolism
  6. 5.1.5 Others
  7. 5.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application
  8. 5.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application
  12. 5.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2021-2032)
  14. 5.3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application (2021-2032)
6 Novel Oral AntiCoagulants (NOAC) Regional Sales and Value Analysis
  1. 6.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2032)
  3. 6.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021-2026
  4. 6.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2027-2032)
  5. 6.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region (2027-2032)
  9. 6.5 Global Novel Oral AntiCoagulants (NOAC) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032)
  12. 6.6.2 North America Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032)
  15. 6.7.2 Europe Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032)
  21. 6.9.2 South America Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2025 VS 2032
7 Novel Oral AntiCoagulants (NOAC) Country-level Sales and Value Analysis
  1. 7.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2032)
  4. 7.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026)
  5. 7.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032)
  6. 7.4 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Armatheon
  2. 8.1.1 Armatheon Company Information
  3. 8.1.2 Armatheon Business Overview
  4. 8.1.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
  6. 8.1.5 Armatheon Recent Developments
  7. 8.2 Aspen
  8. 8.2.1 Aspen Company Information
  9. 8.2.2 Aspen Business Overview
  10. 8.2.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
  12. 8.2.5 Aspen Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Cellceutix
  26. 8.5.1 Cellceutix Company Information
  27. 8.5.2 Cellceutix Business Overview
  28. 8.5.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
  30. 8.5.5 Cellceutix Recent Developments
  31. 8.6 Cosmo Pharmaceuticals
  32. 8.6.1 Cosmo Pharmaceuticals Company Information
  33. 8.6.2 Cosmo Pharmaceuticals Business Overview
  34. 8.6.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  36. 8.6.5 Cosmo Pharmaceuticals Recent Developments
  37. 8.7 CSL Behring
  38. 8.7.1 CSL Behring Company Information
  39. 8.7.2 CSL Behring Business Overview
  40. 8.7.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
  42. 8.7.5 CSL Behring Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Marathon Pharmaceuticals
  50. 8.9.1 Marathon Pharmaceuticals Company Information
  51. 8.9.2 Marathon Pharmaceuticals Business Overview
  52. 8.9.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  54. 8.9.5 Marathon Pharmaceuticals Recent Developments
  55. 8.10 Ockham Biotech
  56. 8.10.1 Ockham Biotech Company Information
  57. 8.10.2 Ockham Biotech Business Overview
  58. 8.10.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
  60. 8.10.5 Ockham Biotech Recent Developments
  61. 8.11 Perosphere
  62. 8.11.1 Perosphere Company Information
  63. 8.11.2 Perosphere Business Overview
  64. 8.11.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
  66. 8.11.5 Perosphere Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 Bayer
  74. 8.13.1 Bayer Company Information
  75. 8.13.2 Bayer Business Overview
  76. 8.13.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
  78. 8.13.5 Bayer Recent Developments
  79. 8.14 GSK
  80. 8.14.1 GSK Company Information
  81. 8.14.2 GSK Business Overview
  82. 8.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
  84. 8.14.5 GSK Recent Developments
  85. 8.15 Johnson & Johnson
  86. 8.15.1 Johnson & Johnson Company Information
  87. 8.15.2 Johnson & Johnson Business Overview
  88. 8.15.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
  90. 8.15.5 Johnson & Johnson Recent Developments
  91. 8.16 Sanofi
  92. 8.16.1 Sanofi Company Information
  93. 8.16.2 Sanofi Business Overview
  94. 8.16.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
  96. 8.16.5 Sanofi Recent Developments
  97. 8.17 Eisai
  98. 8.17.1 Eisai Company Information
  99. 8.17.2 Eisai Business Overview
  100. 8.17.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
  102. 8.17.5 Eisai Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Novel Oral AntiCoagulants (NOAC) Value Chain Analysis
  2. 9.1.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Novel Oral AntiCoagulants (NOAC) Sales Mode & Process
  6. 9.2 Novel Oral AntiCoagulants (NOAC) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
  9. 9.2.3 Novel Oral AntiCoagulants (NOAC) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst